Cardiovascular disease remains the leading cause of death globally, but emerging evidence suggests we've been treating symptoms rather than addressing a fundamental driver: chronic inflammation within coronary arteries and heart tissue itself. This paradigm shift could revolutionize how millions of adults approach heart health prevention and treatment. Advanced artificial intelligence algorithms are now capable of detecting inflammatory markers in standard cardiac imaging that were previously invisible to human interpretation. These AI-enhanced scans can identify patients at high cardiovascular risk years before traditional markers like cholesterol levels or blood pressure would suggest concern. The technology analyzes subtle tissue patterns and vascular changes that correlate with inflammatory activity, essentially providing a window into the biological processes that precede heart attacks and strokes. Simultaneously, targeted immunomodulatory drugs are showing promise in clinical applications, moving beyond the broad anti-inflammatory approaches of the past to precisely modulate specific immune pathways involved in cardiovascular inflammation. This represents a significant evolution from the lipid-centric model that has dominated cardiology for decades. The inflammation-focused approach aligns with growing understanding of how metabolic dysfunction, autoimmune processes, and chronic stress contribute to cardiovascular disease through inflammatory mechanisms. However, key questions remain about optimal timing for intervention, which inflammatory markers provide the most predictive value, and how to balance immune suppression with maintaining protective immune function. The clinical challenge lies in translating these laboratory insights into practical screening and treatment protocols that can be implemented across diverse healthcare settings while ensuring cost-effectiveness and patient safety.